Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05962242 · ClinicalTrials.gov registry record · Phase 2
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
A Phase 2 study of Squamous Cell Carcinoma of the Oropharynx, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 5
- Study locations
NCT05962242: Recruiting Phase 2 study of Squamous Cell Carcinoma of the Oropharynx, sponsored by University of Virginia.
NCT05962242 is a Phase 2 study of Squamous Cell Carcinoma of the Oropharynx that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 90 participants, above the 64-participant average among 6 other Squamous Cell Carcinoma of the Oropharynx trials with a reported enrollment target (41% higher). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05962242, a Phase 2 study of Squamous Cell Carcinoma of the Oropharynx, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 5
- Study locations
Study Summary
The study will evaluate the safety and effectiveness of a lower than standard dose of radiation for definitive or adjuvant treatment of head and neck squamous cell carcinomas.
Primary Outcome
Incidence of disease free survival as measured by circulating HPV on Nav Dx blood tests.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (5)
Virginia
- University of Virginia - Charlottesville
- Eastern Virginia Medical School - Norfolk
- Bon Secours - Richmond
- Virginia Commonwealth University - Richmond
Florida
- Miami Cancer Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-06-28 |
| Est. Completion | 2029-11-01 |
| Phase | Phase 2 |
What NCT05962242 shows while recruiting
NCT05962242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 64-participant average among 6 other Squamous Cell Carcinoma of the Oropharynx trials with a reported enrollment target (41% higher).
The record links to 1 condition, with Squamous Cell Carcinoma of the Oropharynx appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT05962242 lists 5 locations in 2 states (Virginia, Florida).
Frequently Asked Questions
What is clinical trial NCT05962242 about?
NCT05962242 is a clinical study titled "HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma". The study will evaluate the safety and effectiveness of a lower than standard dose of radiation for definitive or adjuvant treatment of head and neck squamous cell carcinomas.
What is the current status of trial NCT05962242?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-06-28. Estimated completion is 2029-11-01.
What conditions does trial NCT05962242 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of the Oropharynx.
What interventions are being tested in trial NCT05962242?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05962242?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05962242 being conducted?
This trial has 5 study locations across Florida, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of the Oropharynx
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
RECRUITING · Phase 2
-
Safety and Efficacy of APG-157 in Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
ACTIVE NOT RECRUITING · NA
-
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
COMPLETED · Phase 1
-
Saliva-based Detection of CD44
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI